Front Oncol: Evaluation of the efficacy of resectable pancreatic cancer with lymph node metastasis or R1 resection using adjuvant chemotherapy followed by radiotherapy and chemotherapy

The prognosis of pancreatic cancer is very poor, with a 5-year survival rate of only 10-25%

The prognosis of pancreatic cancer is very poor, with a 5-year survival rate of only 10-25%

The study included 266 patients with resectable pancreatic cancer with lymph node metastasis or R1 resection

The study included 266 patients with resectable pancreatic cancer with lymph node metastasis or R1 resection

The median OS of patients with tumors located in the head of the pancreas was 19.

 OS comparison

In multivariate Cox regression analysis, pancreatic body or tail tumor (HR=0.

In multivariate Cox regression analysis, pancreatic body or tail tumor (HR=0.

OS related factors analysis

Propensity score matching was performed on 122 patients to explore the role of CRT

Propensity score matching was performed on 122 patients to explore the role of CRT

PSM vs.

In summary, studies have shown that for patients with resectable pancreatic cancer accompanied by lymph node metastasis or R1 resection, postoperative adjuvant chemotherapy and continuous radiotherapy (CT-CRT) can improve the patient’s OS, which is worthy of further discussion

Original source:

Xing J, Yang B, Hou X, et al.

Xing J, Yang B, Hou X, et al.
(2021) Prognostic Factors and Effect of Adjuvant Chemoradiation Following Chemotherapy in Resected Pancreatic Cancer Patients With Lymph Node Metastasis or R1 Resection.
Front.
Oncol.
11:660215.
doi: 10.
3389/fonc .
2021.
660215.


Leave a message here